← Leaderboards
Erica J Young
Myosin Therapeutics Inc.
$4,679,499
Attributed
$4,679,499
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,679,499 · 2
By mechanism
R44$4,679,499 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Innovation”
- Klaus Romero · Critical Path Institute$86,053,372
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$69,953,681
- Tony Moody · Duke University$65,625,959
- Matthew Johnson · Duke University$60,590,296
Research focus
InnovationModalityDrug DevelopmentHospital CostsMethamphetamineMethamphetamine UseDoseAftercareEconomic ImpactFundingInpatientsMedication AdministrationCost EstimateCostAbstinenceCause Of DeathBehavior TherapyBiologyDrug UsageBrainEnvironmentFda ApprovedCriminal JusticeMolecular Motors
Grant awards (5)
Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2$1,496,586
R44 · FY2025 · DA · contact PI
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$1,208,298
R44 · FY2023 · DA · contact PI
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$440,888
R44 · FY2023 · DA · contact PI
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$1,208,298
R44 · FY2022 · DA · contact PI
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$325,429
R44 · FY2021 · DA · contact PI